Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Publisher Correction: Oncologists greet Lumakras: the world’s first KRAS inhibitor

The Original Article was published on 09 September 2021

Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-021-01053-9, published online 9 September 2021.

In the version of this News article initially published, the article should have stated that in addition to Qiagen’s Therascreen, the FDA also approved Guardant360 CDx from Guardant Health, as companion diagnostics for Lumakras. In the fourth paragraph, in the third sentence beginning “It is approved for use with a companion diagnostic,” the end of the sentence has been amended to include “or Guardant360 CDx from Guardant Health.”

The online version of the article has been updated.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Cormac Sheridan.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sheridan, C. Publisher Correction: Oncologists greet Lumakras: the world’s first KRAS inhibitor. Nat Biotechnol (2021). https://doi.org/10.1038/s41587-021-01120-1

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing